These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 30387880)

  • 1. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
    Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
    Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
    Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
    J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
    Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
    Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
    Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
    Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study.
    Jiang T; Cheng R; Zhang G; Su C; Zhao C; Li X; Zhang J; Wu F; Chen X; Gao G; Li W; Cai W; Zhou F; Zhao J; Xiong A; Ren S; Zhang G; Zhou C; Zhang J
    Clin Lung Cancer; 2017 Nov; 18(6):631-639.e2. PubMed ID: 28549835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
    Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
    Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
    Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
    Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J;
    Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
    Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.
    Zhang G; Cheng R; Zhang Z; Jiang T; Ren S; Ma Z; Zhao S; Zhou C; Zhang J
    Sci Rep; 2017 Feb; 7():42979. PubMed ID: 28211502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
    Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
    Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
    Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.